Cover Image
市場調查報告書

肌肉萎縮症:開發中產品分析

Muscular Dystrophy - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 227546
出版日期 內容資訊 英文 138 Pages
訂單完成後即時交付
價格
Back to Top
肌肉萎縮症:開發中產品分析 Muscular Dystrophy - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 138 Pages
簡介

肌肉萎縮症,是進入遺傳性疾病組,肌肉組織容易受到損壞,損傷的肌肉變弱的進行性疾病。通常6歲症狀呈現,幼兒期的早期階段發生。疲勞感和學習障礙,智力障礙,肌肉無力,伴隨進行性的步行困難。

本報告提供肌肉萎縮症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的新聞和發表開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

簡介

  • 調查範圍

肌肉萎縮症概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9368IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 27 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 4 molecules, respectively.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Muscular Dystrophy - Overview
  • Muscular Dystrophy - Therapeutics Development
  • Muscular Dystrophy - Therapeutics Assessment
  • Muscular Dystrophy - Companies Involved in Therapeutics Development
  • Muscular Dystrophy - Drug Profiles
  • Muscular Dystrophy - Dormant Projects
  • Muscular Dystrophy - Discontinued Products
  • Muscular Dystrophy - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Muscular Dystrophy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Muscular Dystrophy - Pipeline by Acceleron Pharma Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H1 2017
  • Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H1 2017
  • Muscular Dystrophy - Pipeline by aTyr Pharma Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Benitec Biopharma Ltd, H1 2017
  • Muscular Dystrophy - Pipeline by Bio Blast Pharma Ltd, H1 2017
  • Muscular Dystrophy - Pipeline by Biophytis SAS, H1 2017
  • Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Evotec AG, H1 2017
  • Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
  • Muscular Dystrophy - Pipeline by Genethon SA, H1 2017
  • Muscular Dystrophy - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Marina Biotech Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Medestea Research & Production SpA, H1 2017
  • Muscular Dystrophy - Pipeline by Novogen Ltd, H1 2017
  • Muscular Dystrophy - Pipeline by Pfizer Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Prothelia Inc, H1 2017
  • Muscular Dystrophy - Pipeline by SanBio Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2017
  • Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Muscular Dystrophy - Pipeline by Strykagen Corp, H1 2017
  • Muscular Dystrophy - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
  • Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd, H1 2017
  • Muscular Dystrophy - Dormant Projects, H1 2017
  • Muscular Dystrophy - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Muscular Dystrophy - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Muscular Dystrophy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top